SARS-COV-2 VARIANTS OF CONCERN-SPECIFIC MULTI-ANTIGENS UNIVERSAL VACCINE
Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CDS T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and/or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and/or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).
1 .- 30 . (canceled)
31 . A pre-emptive pan-coronavirus vaccine composition, the composition comprising, or comprising a sequence encoding: at least two conserved coronavirus antigens selected from: (i) a conserved coronavirus Spike protein; (ii) a conserved coronavirus NSP2 protein; (iii) a conserved coronavirus NSP3 protein; (iv) a conserved coronavirus NSP14 protein; and (v) a conserved coronavirus Nucleoprotein.
32 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus Spike protein; and a conserved coronavirus NSP2 protein.
33 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus Spike protein; and a conserved coronavirus NSP3 protein.
34 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus Spike protein; and a conserved coronavirus NSP14 protein.
35 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus Spike protein; and a conserved coronavirus Nucleoprotein.
36 . (canceled)
37 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus Spike protein; a conserved coronavirus NSP2 protein; and a conserved coronavirus NSP14 protein.
38 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus Spike protein; a conserved coronavirus NSP2 protein; and a conserved coronavirus Nucleoprotein.
39 .- 40 . (canceled)
41 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus Spike protein; a conserved coronavirus NSP14 protein; and a conserved coronavirus Nucleoprotein.
42 .- 43 . (canceled)
44 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus NSP2 protein; and a conserved coronavirus NSP14 protein.
45 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus NSP2 protein; and a conserved coronavirus Nucleoprotein.
46 .- 47 . (canceled)
48 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus NSP14 protein; and a conserved coronavirus Nucleoprotein.
49 . (canceled)
50 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus NSP2 protein; a conserved coronavirus NSP3 protein; and a conserved coronavirus Nucleoprotein.
51 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus NSP2 protein; a conserved coronavirus NSP14 protein; and a conserved coronavirus Nucleoprotein.
52 . The composition of claim 31 , wherein the at least two conserved coronavirus antigens are: a conserved coronavirus NSP3 protein; a conserved coronavirus NSP14 protein; and a conserved coronavirus Nucleoprotein.
53 .- 57 . (canceled)
58 . The composition of claim 31 further comprising a T cell attracting chemokine, wherein the T cell attracting chemokine is CCL5, CXCL9, CXCL10, CXCL11, or a combination thereof.
59 . The composition of claim 31 further comprising a composition that promotes T cell proliferation and T-cell memory, wherein the composition that promotes T cell proliferation and memory is IL-7, IL-2, or IL-15.
60 . The composition of claim 31 , wherein the conserved protein or antigen is conserved among human and animal coronaviruses.
61 .- 64 . (canceled)
65 . The composition of claim 31 , wherein the composition comprises one of SEQ ID NO: 64-116.
66 .- 77 . (canceled)
78 . A pre-emptive pan-coronavirus vaccine composition, the composition comprising, or comprising a sequence encoding one or more large sequence coronavirus proteins, wherein the one or more large sequence coronavirus proteins comprise: a conserved coronavirus Spike protein; a conserved coronavirus NSP2 protein; a conserved coronavirus NSP14 protein; and a conserved coronavirus Nucleoprotein.
79 . A method of preventing infection or reinfection by one or more coronavirus variants or subvariants in a subject, said method comprising administering a therapeutically effective amount of a composition according claim 31 .